Objective To explore the clinical efficacy of montelukast sodium combined with Pediatric Dingchuan Oral Liquid in the treatment of children with cough variant asthma.Methods A total of 68 children with cough variant asthma admitted to the Pediatrics Department of Sanmenxia Central Hospital from January 2022 to January 2024 were randomly divided into an observation group and a control group,with 34 cases in each group.The control group was treated with montelukast sodium,while the observation group was treated with Pediatric Dingchuan Oral Liquid in addition to the treatment in the control group.The treatment outcomes,clinical indicators,and immunoglobulin levels were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).The clinical indicators'duration in the observation group was shorter than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the serum levels of immunoglobulin A and immunoglobulin G increased,and the serum level of immunoglobulin E decreased in both groups.Moreover,the serum levels of immunoglobulin A and immunoglobulin G in the observation group were higher than those in the control group,and the serum level of immunoglobulin E was lower than that in the control group,with statistically significant differences(P<0.05).Conclusion Montelukast sodium combined with Pediatric Dingchuan Oral Liquid has a good effect on children with cough variant asthma,which is beneficial for reducing the duration of sputum,cough,and hospitalization,and can improve the serum levels of immunoglobulin E,immunoglobulin A,and immunoglobulin G in children.